艾迪药业：预计2025年度亏损同比下降约88.67%至83.00%

Core Viewpoint - Eddie Pharmaceuticals (688488.SH) expects a significant reduction in losses for the fiscal year 2025, with projected revenues increasing substantially compared to the previous year [1] Financial Performance - The company anticipates total revenue for 2025 to be approximately 721.01 million yuan, an increase of about 303.21 million yuan or 72.57% year-on-year [1] - Revenue from innovative anti-HIV drugs is expected to reach approximately 285.31 million yuan, reflecting a year-on-year increase of 90.34% [1] - The revenue from the subsidiary Nanjing Nanda Pharmaceutical Co., Ltd. is projected to be around 299.84 million yuan, with a year-on-year increase of 227.38% [1] Profitability Outlook - The company forecasts a net loss attributable to shareholders of approximately 16.00 million to 24.00 million yuan for 2025, which represents a reduction in losses of about 125.20 million to 117.20 million yuan, translating to a year-on-year decrease in loss margin of approximately 88.67% to 83.00% [1] - The expected net loss attributable to shareholders, excluding non-recurring gains and losses, is projected to be around 17.20 million to 25.20 million yuan, indicating a reduction in losses of approximately 131.25 million to 123.25 million yuan, with a year-on-year decrease in loss margin of about 88.41% to 83.02% [1]